



# Cardiac Outcomes in a Cohort of Children with MIS-C

Tanu Singhal<sup>1</sup> · Tanuja Karande<sup>2</sup> · Prashant Bobhate<sup>2</sup> · Preetha Joshi<sup>3</sup>

Received: 29 April 2023 / Accepted: 30 June 2023 / Published online: 13 July 2023  
© The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation 2023

*To the Editor:* We aimed to study cardiac outcomes of children with Multisystem inflammatory syndrome (MIS-C) at our centre. We included all children diagnosed with MIS-C at our centre in 2020-2021. The diagnosis and treatment was as per standard guidelines [1]. All patients underwent ECHO at baseline, 48-72 h, 2 wk, 4-6 wk and if abnormal, every 3-6 mo. The patients were followed up till December 2022.

Twenty-seven patients were diagnosed with MIS-C (10 in 2020 and 17 in 2021) with ages between 1-17 y (mean 7 y). Fifteen had a Kawasaki disease phenotype while 12 had a toxic shock phenotype. Nineteen patients received intravenous immunoglobulin (IVIG) and steroids and eight only steroids. The baseline ECHO was abnormal in 15 (55%) patients. The ECHO abnormalities included reduced ejection fraction (REF) in 10, coronary artery dilatation (Z score >2) in 7 and both in 3 patients. The lowest EF was 35% and Z score ranged from 2-2.5. All children survived and all were followed up till December 2022. The REF function normalized at 2 wk in 5 (50%) and at 3, 6, 12 and 18 mo in 1 each. Only 1 patient had low voltage QRS complex at 18 mo. The coronary artery dilatation resolved by 2 wk in 4 patients and by 6 wk, 3 and 12 mo in 1 each.

The incidence of baseline cardiac abnormalities in our cohort (55%) is similar to that reported in a recent systematic review [2]. The findings of our study are similar to other cohorts which have reported normalization of ECHO abnormalities by 6 mo in most patients [3]. However, some studies have reported residual abnormalities in global longitudinal strain (GLS) and cardiac MRI in 20-50% of patients at 6 mo

follow up [4]. The long term consequences of these findings remains to be seen.

## Declarations

**Conflict of Interest** None.

## References

1. Indian Academy of Paediatrics. Multi-system Inflammatory Syndrome in Children (MIS-C): Statement by Indian Academy of Pediatrics (April 2021). Available at: [https://iapindia.org/pdf/yOQBzDmtbU4R05M\\_IAP%20Covid%2019%20managementGuidelines%20for%20Pediatrician%20V1.1%20Apr%2027\\_2021%20%28%29.pdf](https://iapindia.org/pdf/yOQBzDmtbU4R05M_IAP%20Covid%2019%20managementGuidelines%20for%20Pediatrician%20V1.1%20Apr%2027_2021%20%28%29.pdf). Accessed on 16 Apr 2023.
2. Arantes Junior MAF, Conegundes AF, Branco Miranda BC, et al. Cardiac manifestations in children with the multisystem inflammatory syndrome (MIS-C) associated with SARS-CoV-2 infection: systematic review and meta-analysis. *Rev Med Virol.* 2023;33:e2432.
3. Yasuhara J, Masuda K, Watanabe K, et al. Longitudinal cardiac outcomes of multisystem inflammatory syndrome in children: a systematic review and meta-analysis. *Pediatr Cardiol.* 2023;44:892–907.
4. Benvenuto S, Simonini G, Della Paolera S, et al. Cardiac MRI in midterm follow-up of MIS-C: a multicenter study. *Eur J Pediatr.* 2023;182:845–54.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

✉ Tanu Singhal  
tanusinghal@yahoo.com

<sup>1</sup> Department of Pediatrics, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India

<sup>2</sup> Department of Pediatric Cardiology, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India

<sup>3</sup> Department of Pediatric Intensive Care, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India